MicrosoftTeams-image (5).png
Venous Procedure Devices Market Poised for US$ 3.4 Billion Growth with a CAGR of 6% by 2030: As per TMR Study
June 02, 2023 06:30 ET | Transparency Market Research
Wilmington, Delaware, United States, June 02, 2023 (GLOBE NEWSWIRE) -- The market for venous procedure devices is expected to reach US$ 3.4 billion by 2030. From 2020 to 2030, the Venous Procedure...
Peripheral Artery Disease Market.png
Global Peripheral Artery Disease (PAD) Devices Market to Reach USD 7.80 Billion by 2030, States a Report by Next Move Strategy Consulting
July 12, 2022 09:16 ET | Next Move Strategy Consulting
New York, July 12, 2022 (GLOBE NEWSWIRE) -- According to the report published by Next Move Strategy Consulting, the global peripheral artery disease (PAD) devices market accrued USD 4.02 billion in...
Early Evaluation of
Early Evaluation of Transcarotid Artery Revascularization (TCAR) Versus Carotid Endarterectomy (CEA) Cost-Effectiveness
December 27, 2021 08:15 ET | Society for Vascular Surgery
Rosemont, Ill., Dec. 27, 2021 (GLOBE NEWSWIRE) -- A cost-effectiveness model based on peer-reviewed sources suggests that although five-year costs for transcarotid artery revascularization (TCAR)...
Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease
October 19, 2021 09:18 ET | Ambulero
MIAMI, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ambulero Inc., a biotechnology company (“Ambulero” or the “Company”) developing new cell and gene therapy treatments for patients suffering from severe...
Study of patients un
Study of patients undergoing abdominal aortic aneurysm repair suggests screening guidelines may be inadequate
January 05, 2021 09:15 ET | Society for Vascular Surgery
Rosemont, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) -- A retrospective study analyzing approximately 55,000 patients undergoing abdominal aortic aneurysm (AAA) repair suggests current AAA screening...
Two Clinical Sites in Mexico City Join Endovasc's Liprostin Phase II Trial
January 28, 2004 08:30 ET | Endovasc Inc.
MONTGOMERY, Texas, Jan. 28, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today that...